60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Rhea-AI Summary
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported second quarter 2026 results for the period ended June 30, 2026. Net product revenues were approximately $208 thousand, up about 106% from approximately $101 thousand in the second quarter of 2025. Gross profit on product revenues was approximately $57 thousand, compared with about $51 thousand a year earlier.
Operating expenses were approximately $2.33 million, up from about $1.86 million in the prior-year quarter. Net loss attributable to common stockholders was approximately $2.40 million, or $0.90 per share, versus a net loss of about $1.84 million, or $5.01 per share, in the second quarter of 2025.
The company develops medicines for vector-borne diseases and markets ARAKODA (tafenoquine) for malaria prevention, with three active clinical trials underway for babesiosis.
Positive
- Net product revenue increased ~106% YoY to about $208 thousand in Q2 2026
- Gross profit on product revenues rose to approximately $57 thousand from about $51 thousand
- Lead product ARAKODA (tafenoquine) is FDA‑approved for malaria prevention and sold in the U.S. and Australia
- Company reports three active clinical trials underway for babesiosis, an emerging tick‑borne disease
Negative
- Operating expenses increased to approximately $2.33 million from about $1.86 million YoY
- Net loss attributable to common stockholders widened to about $2.40 million from roughly $1.84 million
- Despite revenue growth, net loss per share was $0.90 in Q2 2026
Market Reaction – SXTP
Following this news, SXTP has gained 0.42%, reflecting a mild positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.20. Trading volume is elevated at 2.7x the average, suggesting notable buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | 1Q26 earnings | Negative | -4.8% | Revenue declined while operating expenses and net loss increased year over year. |
| Nov 13 | 3Q25 earnings | Negative | -4.9% | Revenue growth was offset by gross loss, higher expenses, and increased net loss. |
| Aug 13 | 2Q25 earnings | Negative | -3.0% | Revenue declined despite improved gross profit, operating expenses, and net loss. |
| May 15 | 1Q25 earnings | Neutral | +14.9% | Revenue and gross profit increased, but the company reported a net loss. |
| Nov 14 | 3Q24 earnings | Negative | -3.1% | Revenue and gross profit improved, but operating expenses and net loss remained substantial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific history showed negative 24-hour reactions in 4 of 5 earnings events, with an average move of -0.16%.
Key Terms
clinical trials medical
vector-borne diseases medical
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026.
Financial Highlights for the Quarter Ended June 30, 2026:
- Net product revenues increased approximately
106% to approximately$208 thousand for the second quarter of 2026, from approximately$101 thousand for the second quarter of 2025. - Gross profit on product revenues was approximately
$57 thousand for the second quarter of 2026, compared with approximately$51 thousand for the second quarter of 2025. - Operating expenses were approximately
$2.33 million for the second quarter of 2026, compared with approximately$1.86 million for the second quarter of 2025. - Net loss attributable to common stockholders was approximately
$2.40 million , or$0.90 per share, for the second quarter of 2026, compared with a net loss of approximately$1.84 million , or$5.01 per share, for the second quarter of 2025.
Additional information regarding the Company's results is available in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Media Contact:
Kristen Landon
kristenlandon@60degreespharma.com
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
